Efficacy and Safety of XE...

Individuals with epilepsy, when treated with existing antiseizure drugs, continue to experience seizures. Hence, there is an urgent demand for more potent medications, particularly those capable of significantly reducing seizures or even achieving complete seizure freedom. These drugs operate by affecting various molecular sites within the brain. One particularly promising target is the Kv7.2/Kv7.3 voltage-gated potassium channels, which play a crucial role in reducing excessive neuronal excitability and are associated with genetic conditions that lead to seizures. Augmenting the function of these channels has demonstrated potential in reducing seizures, although the initial generation drug, ezogabine, had long-term adverse effects and was withdrawn from the market.